12 Biotech Stocks with the Biggest Upside Potential

Page 3 of 11

9. Denali Therapeutics, Inc. (NASDAQ:DNLI)

Analyst Upside: 89.71%

Number of Hedge Fund Holders: 23

Denali Therapeutics, Inc. (NASDAQ:DNLI) develops and commercializes product candidates for neurodegenerative diseases. Its product portfolio includes LRRK2, RIPK1, TREM2, and Tau.

The company expects to submit its first biologics license agreement (BLA) for tividenofusp alfa for Hunter syndrome and prepare for commercial launch. It is also seeking alignment with the FDA to attain an accelerated approval path for its second program, DNL126, for Sanfilippo syndrome. These two programs are anticipated to develop into a profitable franchise of TransportVehicleTM (TV) enabled enzyme replacement therapies for the company.

Denali Therapeutics, Inc. (NASDAQ:DNLI) is expanding its TV-enabled portfolio of therapeutic enzymes, oligonucleotides, and antibodies. It plans to advance 1-2 additional TV programs into the clinic each year for the next three years. This TV platform holds considerable potential to deliver a new class of barrier-crossing therapeutics, which is why analysts are optimistic about its operations. Denali Therapeutics, Inc. (NASDAQ:DNLI) takes the ninth spot on our list of the 12 biotech stocks with the biggest upside potential.

Page 3 of 11